Navigation Links
Masimo Reports Third Quarter 2008 Financial Results
Date:10/27/2008

mers; the amount and type of equity awards that we may grant to employees and service providers in the future; and other factors discussed in the "Risk Factors" section of our Quarterly Report on Form 10-Q for the fiscal quarter ended June 28, 2008 filed with the Securities and Exchange Commission on August 5, 2008. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We do not undertake any obligation to update, amend or clarify these forward-looking statements or the risk factors contained in our Quarterly Report on Form 10-Q for the fiscal quarter ended June 28, 2008, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.

Masimo Corporation

Investor Contact:

Mark P. de Raad

Executive Vice President and Chief Financial Officer

Masimo Corporation

(949) 297-7080

mderaad@masimo.com

Media Contact:

Dana Banks

Manager, Public Relations

Masimo Corporation

(949) 297-7348

dbanks@masimo.com

Masimo, SET, Signal Extraction Technology, Improving Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications, Rainbow, SpHb, SpCO, SpMet, PVI, Pulse CO-Oximetry and Pulse CO-Oximeter are trademarks or registered trademarks of Masimo Corporation.

MASIMO CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands)


'/>"/>
SOURCE Masimo Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. New Clinical Studies Presented at the American Society of Anesthesiology (ASA) Annual Meeting Show Masimo Technologies Provide Advanced Clinical Intelligence
2. Five New Clinical Studies Show Value of Masimo PVI & PI
3. Masimo to Report Third Quarter 2008 Financial Results on October 27, 2008
4. Masimo Initiates Limited Release of First-Ever Noninvasive and Continuous Hemoglobin Monitors
5. Masimo Announces Desaturation Index 3D Alarm as Standard Feature in All Radical-7 Pulse CO-Oximetry Devices
6. Masimo to Present at Goldman Sachs 29th Annual Global Healthcare Conference
7. Masimo to Present at Deutsche Bank 33rd Annual Health Care Conference
8. Masimo Reports First Quarter 2008 Financial Results
9. Atom Medical Adopts Masimo Rainbow SET Technology
10. Schiller AG Adopts Masimo Rainbow SET as Their Technology Platform of Choice for Patient Monitoring Devices Worldwide
11. Masimo to Present at Citi Investment Research 5th Annual Small & Mid-Cap Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2015)... CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) ... today announced data from PERSIST-1 – a randomized Phase ... myelofibrosis – in a late-breaking oral session at the ... Clinical Oncology (ASCO), May 29-June 2, 2015 in ... oral multikinase inhibitor with specificity for JAK2 and FLT3. ...
(Date:5/30/2015)... CHICAGO and RARITAN, N.J. ... the international, multi-center, open-label, two-part, single-arm Phase 2 ... – an investigational, human anti-CD38 monoclonal antibody – ... percent (95% CI, 20.8-38.9), as assessed by an ... multiple myeloma. The ORR was consistent among the ...
(Date:5/30/2015)... 2015  Caris Life Sciences® today announced the ... researchers identified biomarker changes, including key driver mutations, ... changes in response to therapy as the disease ... subset of a larger study analyzing 1,245 glioma ... These data utilizing Caris Molecular Intelligence®, the company,s ...
(Date:5/29/2015)... HILL, N.C. , May 29, 2015 /PRNewswire/ ... medical affairs function into roles involving clinical development, ... As its responsibilities have grown, Medical Affairs has ... function as a global group. And while its ... find it challenging to identify strong performance metrics ...
Breaking Biology Technology:Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 2Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 3Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 4Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 5Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 6Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 7Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 8Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 9Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 10Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 2Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 3Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 4Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 5Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 6Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 7Caris Life Sciences Paired Tumor Data Identifies Key Driver Mutations and Confirms Tumor Heterogeneity in High-Grade Glioma Samples 2Caris Life Sciences Paired Tumor Data Identifies Key Driver Mutations and Confirms Tumor Heterogeneity in High-Grade Glioma Samples 3Caris Life Sciences Paired Tumor Data Identifies Key Driver Mutations and Confirms Tumor Heterogeneity in High-Grade Glioma Samples 4Creating an Effective Pharmaceutical Medical Affairs Group with Global Capabilities 2
... N.C. A genetic tool used by medical researchers may ... microbes and viruses from drinking water. , In a series ... of genetic material could successfully target a matching portion of ... make it stop working. If this new approach can be ...
... - YM BioSciences Inc.,(AMEX: YMI , TSX: ... and commercializes differentiated products for patients worldwide,today announced ... its,anti-cancer drug nimotuzumab, a humanized monoclonal antibody that ... the 2008 American,Society of Clinical Oncology (ASCO) Annual ...
... presentation at the 14th,International Conference on Prenatal Diagnosis and ... Diagnostic.,I.D.Rh(D) is the first in a series of noninvasive ... maternal blood sample., The I.D.Rh(D) test diagnoses the ... and can be performed as early as ten weeks ...
Cached Biology Technology:Possible new approach to purifying drinking water 2Possible new approach to purifying drinking water 3NIMOTUZUMAB CLINICAL DATA PRESENTED AT ASCO ANNUAL MEETING 2NIMOTUZUMAB CLINICAL DATA PRESENTED AT ASCO ANNUAL MEETING 3NIMOTUZUMAB CLINICAL DATA PRESENTED AT ASCO ANNUAL MEETING 4Presentation at the 14th International Conference on Prenatal Diagnosis and Therapy Highlights Biocept's I.D.Rh(D) Prenatal Diagnostic 2
(Date:5/29/2015)... , May 28, 2015 Research and ... of the "Facial Recognition Market by Solution, ... Global Forecast to 2020" report to their ... seen facial recognition technology become more efficient and ... gain traction and investment from the commercial sector. ...
(Date:5/28/2015)... GLEN ALLEN, Va. , May 28, 2015 ... announced the release of a new report titled ... self-healing materials (reversible polymers, inorganic capsule and vascular ... self-healing coatings) will grow to around $2.7 billion ... latest deliverable from n-tech,s extensive coverage of smart ...
(Date:5/27/2015)... 2015   Codonics (codonics.com), a ... image documentation solutions and Omnicell  (omnicell.com), ... solutions, is pleased to announce their state ... Label System® (SLS), an award-winning FDA class ... Omnicell Anesthesia Workstation, helps prevent medication errors, ...
Breaking Biology News(10 mins):Global advanced Facial Recognition Market Expected to Grow From $2.77 Billion in 2015 to $6.19 Billion in 2020, at an Estimated CAGR of 17.4% 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 3Codonics and Omnicell Expand Partnership 2Codonics and Omnicell Expand Partnership 3Codonics and Omnicell Expand Partnership 4
... by the problem of "super-bugs" - bacteria that have ... that a high rate of antibiotic prescribing in hospitals ... for some antibiotics, an even more important factor contributing ... the open access international medical journal PLoS Medicine, is ...
... have made an important discovery that will advance our ... of breast cancer cells. The research, in collaboration with ... (IRCM) identifies 153 genes that respond to estrogen and ... the growth of breast cancer cells. The study, published ...
... such as corn, soybeans and sunflowers into fuel uses ... generates, according to a new Cornell University and University ... benefit to using plant biomass for liquid fuel," says ... "These strategies are not sustainable." , Pimentel and Tad ...
Cached Biology News:Agricultural antibiotic use contributes to 'super-bugs' in humans 2Scientists discover genetic pathway responsible for breast cancer cell growth 2Using the genomic shortcut to predict bacterial behavior 2
... A perfect complement to high-speed analytical techniques, the AutoTrace SPE is a powerful, ... the cartridge conditioning, sample loading and elution steps for large volumes aqueous solution ... ... ...
... optically clear polystyrene with frosted labeling ... for cell counting. 100% integrity tested. ... new product number, created to easily ... no availability yet, please order under ...
Cell Culture Flask, nontreated polystyrene...
... The Corning CellBIND surface is produced ... a more hydrophilic surface giving more consistent, ... yields. CellBIND enhances cell attachment and growth ... serum-free medium. • CellBIND may provide a ...
Biology Products: